KEYNOTE-716
14 Dec 2020
MK-3475-716
NCT03553836
Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma
Merck Sharp & Dohme Corp.
Cancer Type | Melanoma & other skin |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 12 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | All stages |
Anticipated Start Date | 2018-09-12 |
Anticipated End Date | 2033-10-21 |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Professor Michael Brown |
Recruitment Status | Recruiting |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Brian Stein |
Recruitment Status | Recruiting |